Abstract:Programmed death-ligand 1 (PD-L1) plays an important role in T cell tolerance and tumor immune escape, which has been reported to be a prognostic factor in various malignancies. However, only a few studies about PD-L1 in nasopharyngeal carcinoma (NPC) are available, and the reported prognostic role of PD-L1 in NPC patients remains controversial. In this study, we aimed to investigate the alterations of PD-L1 expression on tumor cells in NPC patients with and without metastasis. Furthermore, we would explore the correlation of PD-L1 expression on tumor cells and serum Epstein-Barr virus (EBV) DNA load. Pathologically confirmed NPC treated with intensity-modulated radiation therapy were recruited for the study. Formalin-fixed, paraffin-embedded tissues were studied by immunohistochemistry staining. The expression of PD-L1 on tumor cells was detected and the staining results were evaluated by positive tumor cell percentage. Clinical characteristics and qRT-PCR data of serum EBV DNA load before treatment were collected. The optimal cut-off value for PD-L1 staining was determined by the area under the curve of the receiver operating characteristic (ROC). The Chi-square test was used to evaluate results with SPSS 25.0. A total of 78 patients were included in this study, with median follow up 52.8 months (range 12-108 months). The median age was 44 years old (range 22 –65 years). Among those 78 patients, 43(55%) patients had metastasis, 35 (45%) did not have metastasis. PD-L1 expression on tumor cells was detected in 66 patients (66/78, 85%). When staining with PD-L1 on >45% tumor cells, PD-L1 expression was classified as being at a high level according to the ROC curve analysis. In metastasis group, 25 out of 43 patients showed high PD-L1 expression, while in non-metastasis group only 7 out of 35 patients showed high PD-L1 expression (p=0.001). We observed that more patients in metastasis group had detectable serum EBV DNA load than non-metastasis group (p=0.007). In order to study the effect of EBV on PD-L1 expression, we explored the correlation of PD-L1 expression on tumor cells and serum EBV DNA status (before treatment). Our data showed that PD-L1 expression was not significantly correlated with EBV DNA load among all the patients (p= 0.554). Our results revealed that PD-L1 might be a potential metastatic biomarker for NPC patients. Furthermore, EBV status was not significantly correlated with PD-L1 expression. PD-1/PD-L1 pathway might be a promising therapy target for advanced NPC.

Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer

High PD-L1 Expression Predicts Metastasis in Nasopharyngeal Carcinoma

Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma

PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial

PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma

Expression and Clinical Significance of Programmed Death Ligand 1 in Nasopharyngeal Carcinoma.

Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma

Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

PD-1 High Expression Predicts Lower Local Disease Control in Stage IV M0 Nasopharyngeal Carcinoma

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study

Co-expression of PD-1 and PD-L1 Predicts Poor Outcome in Nasopharyngeal Carcinoma

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal carcinoma patients

PD-L1 Associated with the Expression of Cancer Cell-Intrinsic PD-1 and P-S6 Proteins and Predicted a Good Prognosis in Nasopharyngeal Carcinoma

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

The Prognostic Significance of PD-L1 and PD-1 Expression in Patients with Nasopharyngeal Carcinoma: a Systematic Review and Meta-Analysis.

PD-1 and PD-L1 Expression in 132 Recurrent Nasopharyngeal Carcinoma: the Correlation with Anemia and Outcomes.

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment

Elevated IL18 levels in Nasopharyngeal carcinoma induced PD-1 expression on NK cells in TILS leading to poor prognosis